With new, state-of-the-art facilities, extensive tech transfer experience and ongoing investments, Grifols provides contract development and manufacturing services for the production of bulk recombinant proteins for use in diagnostics, therapeutics and vaccines.

Our new, $80 million Consolidated Manufacturing Facility (CMF) is located in Emeryville, California. Surrounded and supported by complementary functions and facilities on the Grifols campus, CMF was designed, built and validated to extend our three decades of reliable current Good Manufacturing Practice (cGMP) production of recombinant proteins into the future. The flexible, multiproduct design of CMF and the available manufacturing capacity created an opportunity to leverage our technical expertise and Grifols’ commitment to quality to provide contract services to biopharma companies as a recombinant protein Contract Development and Manufacturing Organization (CDMO).

READ MORE BY FILLING OUT THE FORM >>>>>